Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.93 and traded as high as $3.41. Puma Biotechnology shares last traded at $3.34, with a volume of 502,104 shares trading hands.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on PBYI. StockNews.com lowered shares of Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a report on Saturday, March 8th. HC Wainwright reissued a "buy" rating and issued a $7.00 price target on shares of Puma Biotechnology in a research note on Friday, February 28th.
View Our Latest Stock Report on PBYI
Puma Biotechnology Stock Performance
The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42. The stock's 50 day moving average price is $3.09 and its 200 day moving average price is $2.94. The company has a market capitalization of $174.13 million, a P/E ratio of 7.31 and a beta of 1.33.
Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported $0.39 EPS for the quarter, beating analysts' consensus estimates of $0.10 by $0.29. The business had revenue of $59.10 million for the quarter, compared to analysts' expectations of $52.50 million. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. As a group, equities analysts expect that Puma Biotechnology, Inc. will post 0.31 EPS for the current year.
Insider Buying and Selling at Puma Biotechnology
In related news, CEO Alan H. Auerbach sold 33,841 shares of the business's stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $106,599.15. Following the completion of the sale, the chief executive officer now directly owns 7,029,674 shares of the company's stock, valued at $22,143,473.10. The trade was a 0.48 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Jeffrey Jerome Ludwig sold 9,437 shares of the company's stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $29,726.55. Following the transaction, the insider now directly owns 108,951 shares in the company, valued at approximately $343,195.65. This trade represents a 7.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 23.70% of the company's stock.
Institutional Trading of Puma Biotechnology
Hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. lifted its stake in shares of Puma Biotechnology by 169.5% in the third quarter. JPMorgan Chase & Co. now owns 48,493 shares of the biopharmaceutical company's stock valued at $124,000 after buying an additional 30,499 shares in the last quarter. SG Americas Securities LLC lifted its position in Puma Biotechnology by 83.9% in the 4th quarter. SG Americas Securities LLC now owns 24,668 shares of the biopharmaceutical company's stock valued at $75,000 after acquiring an additional 11,252 shares in the last quarter. FMR LLC boosted its stake in Puma Biotechnology by 27.1% during the 3rd quarter. FMR LLC now owns 118,265 shares of the biopharmaceutical company's stock valued at $302,000 after purchasing an additional 25,183 shares during the last quarter. Barclays PLC increased its holdings in Puma Biotechnology by 146.5% during the 3rd quarter. Barclays PLC now owns 78,021 shares of the biopharmaceutical company's stock worth $199,000 after purchasing an additional 46,370 shares in the last quarter. Finally, Franklin Resources Inc. purchased a new stake in shares of Puma Biotechnology in the third quarter worth approximately $41,000. Institutional investors and hedge funds own 61.29% of the company's stock.
About Puma Biotechnology
(
Get Free Report)
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
See Also
Before you consider Puma Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Puma Biotechnology wasn't on the list.
While Puma Biotechnology currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
